Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Vaxart ( (VXRT) ) is now available.
On August 14, 2025, Vaxart announced a virtual stockholder fireside chat scheduled for August 20, 2025, to discuss a reverse stock split proposal. Supported by proxy advisory firms ISS and Glass Lewis, the proposal aims to regain Nasdaq compliance. The event will allow stockholders to engage directly with Vaxart’s management and address frequently asked questions.
The most recent analyst rating on (VXRT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall stock score reflects ongoing financial struggles and valuation challenges, offset by positive developments in clinical trials and strategic initiatives. Significant risks remain from operational losses and potential NASDAQ delisting.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered as pills, which can be stored and shipped without refrigeration, eliminating the risk of needle-stick injury. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).
Average Trading Volume: 4,821,640
Technical Sentiment Signal: Sell
Current Market Cap: $82.41M
See more data about VXRT stock on TipRanks’ Stock Analysis page.